India: Vaccination and policy normalisation


India’s consistently above target CPI inflation and US Fed’s hawkish dot plot have revived the domestic policy normalisation debate.
Radhika Rao06 Jul 2021
  • India’s daily Covid case count is back to a tenth of the peak
  • The DBS Weekly Activity Gauge (WAG) is returning to pre-second wave levels
  • Above target CPI inflation and US Fed’s hawkish dot plot have revived the policy normalisation debat
  • Implications for forecasts: Room to stay accommodative is narrowing
  • Implications for investors: Policy normalisation is expected to kickstart in 4Q21
Photo credit: Unsplash


India’s daily Covid case count has moderated to a tenth of the peak. Unlocking is underway, amidst concerns over a third wave and a new Delta plus variant have surfaced. Vaccination remains the central pillar to help the economy move from a second wave driven sequential slump in 1HFY22 to vaccine-led expansion in 2H. This will also dictate the guidance on policy normalisation, which the RBI is likely to build-on for 2HFY22, spurred by sticky inflation and recent US Fed’s pivot.

Vaccination holds the key

India’s daily vaccination rate doubled in June to 3.7mn vs May. In particular, daily inoculation averaged a strong 6mn in the week of June 21, as a new vaccine procurement strategy kicked in. The daily rate has since averaged ~4mn into July, taking the total administered doses to 350mn.



To vaccinate an estimated 920-930mn in the adult population (government’s projection), the supply pipeline needs to be robust. As of July 5, 27% of the population has been vaccinated – 22% with the first dose and 5% with both doses.

Officials were counting on a surge in supplies to 2.16bn doses between August and December 2021, including higher production of Covidshield (Astrazeneca), indigenous Covaxin, and few other in-trail alternatives. The latest update (affidavit to the Supreme Court) suggests that total supply might total 1.35bn i.e. 270mn/ month between August and December 2021 vs ~516mn estimated till July. Until December, the math rests on Covishield (500mn doses), Covaxin (400mn), Sputnik (100mn), rest from Bio E sub-unit (300mn; under trail), Zydus Cadilla (50mn; under trial).

We calculate the various scenarios depending on the daily inoculation rate in 2H21. If we consider the middle of the pack of around 8mn administered doses a day, more than half of the total population and can be covered by end-2021.



Taking stock of the Covid situation:

• The latest national serological survey by the WHO and AIIMS revealed that the seropositivity (i.e. presence of antibodies) rate for persons between 18-59years was at 67%, which was higher at 79% in the urban and 63% in rural areas.

Second wave ebbs: The Covid case count under the second wave has eased sharply, down to a seven-day run-rate of 40-50k cases per day, a tenth of 400k during the peak in May. This has been accompanied by a drop in the overall positivity rate as well as R0 i.e. reproduction rate from May’s highs, easing pressure on the country’s medical infrastructure.



• States are loosening restrictions at a guarded pace, allowing selected contact intensive services e.g. restaurants to reopen but with limitations. Mobility indicators hit a trough in May and have improved into June. Our Weekly Activity Gauge (WAG), calculated using high-frequency Google and Apple mobility indicators alongside the labour participation rate suggests that the prevailing levels are ~5-7% below the pre-pandemic level, after the scale of fall during the second wave was less than the first wave (see chart).



The monthly data heatmap (see below), shows most indicators sans inflation fared well until Apr-May, before feeling the heat from the second wave. June PMIs are a case in point as both manufacturing and services indices weakened due to a combination of lower orders as well as rising input price pressures. Receding base effects has seen exports growth moderate.



Worries over a third wave and Delta plus variant linger: Whilst states mull a cautious unlocking path, concerns over a potential third wave as well as a new variant have surfaced, while the vaccination drive is yet to reach critical mass. A key source of concern is the emergence of Delta plus variant of Covid19 i.e. a sub-lineage of the highly transmissible Delta variant, that was first discovered in India. A handful of cases of the Delta plus variant have been observed in around 12 states according to the Health Ministry, being referred to as a ‘variant of concern’ by the Indian authorities. Selected states have retightened measures in certain provinces, e.g. Maharashtra where cinema theatres remain stay closed, while operating hours for other contact intensive services like restaurants, gyms etc have been shortened, whilst few provinces are under a complete shutdown.

Policy normalisation debate

India’s consistently above target CPI inflation and US Fed’s hawkish dot plot have revived the domestic policy normalisation debate.

CPI inflation has stayed above 4% target since October 2019, keeping the FY20 average inflation at 4.8% and FY21 at 6.2%. Our forecast for FY22 at 5.5% suggests that annual inflation is on course to staying above target for three successive years.

Inflation risks for 2021 remain skewed to the upside, especially core readings, on higher commodities mainly energy, rising input prices, rigidity in fuel taxes and idiosyncratic factors (e.g. temporary spurt owing to the pandemic in medical costs, education, personal services etc.) apart from a likely return in demand impulses as growth gains traction. A normal monsoon and strong domestic production are expected to cool non-imported food pressures beyond the seasonal swings.

Both WPI and CPI inflation indices have quickened in recent months, but the wholesale price index has outpaced retail inflation, as the former is more correlated to global commodities (mainly oil). Wholesale price inflation also impacts manufacturers, who have absorbed most of the input price increases for now, but as recovery gains traction, part of these is beginning to get passed to the consumers (selected consumer durables etc.). An 1 percentage change in WPI core (non-food manufacturing) translates into a small 0.2ppt to CPI core goods inflation and much smaller for overall CPI core and headline inflation, according to a RBI study. While pass-through risks remain low, the monetary policy committee is likely to be concerned that supply-side pressures might be supplanted by demand-led forces as the second wave subsides and sequential growth gains momentum.

Rising inflation benefits borrowers and hurts lenders. Inflation-adjusted real rates have been in negative for more than a year, with the repo rate at 4%, eroding returns from banks’ deposits and incomes, thereby incentivising a push towards riskier assets/investments. Real incomes are also falling, particularly in midst of the pandemic. The bite is harder for the rural consumers where the terms of trade is turning negative as non-food inflation is rising at a faster clip than food (proxy for incomes), whilst fiscal support has been scaled back and the second wave has hit the rural areas more adversely. Minutes of the June policy review were broadly dovish as the members backed the need for policy support to boost recovery amidst the second Covid wave. Inflation was expected to stay elevated but due to supply-side pressures and be temporary.





We note that these remarks were made before the May CPI inflation release, with June numbers (~6%) to be also available by the August meeting. Factoring these in, the RBI monetary policy committee might begin to express more concern over inflation at August’s rate review. As the second wave ebbs and vaccination rate catches up on better supplies, the central bank is likely to outline normalisation plans for 4Q21.

Communication will be key to ensure financial tightness doesn’t front-run the intended speed of normalising policy, emphasising that normalisation does not equate tightening. Draining surplus liquidity is likely to be accompanied by a calibrated increase in the reverse repo rate from the current 3.35% to 3.75% - reinstating the 25bps corridor below the repo rate. Subsequent moves will include a shift in the policy stance from accommodative to neutral, before considering rate hikes. Rate hikes are likely to start in 2H22.


To read the full report, click here to Download the PDF.

Radhika Rao

Economist – India, Indonesia, Thailand & Eurozone
radhikarao@dbs.com


Subscribe here to receive our economics & macro strategy materials.
To unsubscribe, please click here.
The information herein is published by DBS Bank Ltd. It is based on information obtained from sources believed to be reliable, but the Group does not make any representation or warranty, express or implied, as to its accuracy, completeness, timeliness or correctness for any particular purpose. Opinions expressed are subject to change without notice. Any recommendation contained herein does not have regard to the specific investment objectives, financial situation & the particular needs of any specific addressee. The information herein is published for the information of addressees only & is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate legal or financial advice. The Group, or any of its related companies or any individuals connected with the group accepts no liability for any direct, special, indirect, consequential, incidental damages or any other loss or damages of any kind arising from any use of the information herein (including any error, omission or misstatement herein, negligent or otherwise) or further communication thereof, even if the Group or any other person has been advised of the possibility thereof. The information herein is not to be construed as an offer or a solicitation of an offer to buy or sell any securities, futures, options or other financial instruments or to provide any investment advice or services. The Group & its associates, their directors, officers and/or employees may have positions or other interests in, & may effect transactions in securities mentioned herein & may also perform or seek to perform broking, investment banking & other banking or finan­cial services for these companies. The information herein is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation. Sources for all charts & tables are CEIC & Bloomberg unless otherwise specified.

DBS Bank Ltd., 12 Marina Blvd, Marina Bay Financial Center Tower 3, Singapore 018982. Tel: 65-6878-8888. Company Registration No. 196800306E. DBS Bank Ltd., Hong Kong SAR Branch, a company incorporated in Singapore with limited liability. 18th Floor, The Center, 99 Queen’s Road Central, Central, Hong Kong SAR.

The information set out in this website ("Information") is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in any locality, state, country, or other jurisdiction (including but not limited to citizens or residents of the United States of America) where such distribution, publication, availability or use would be contrary to law or regulation. This Information is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction (including but not limited to the United States of America) where such an offer or solicitation would be contrary to law or regulation. This Information is published for general circulation only and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person. Visitors accessing this website should always seek advice from an independent financial adviser regarding the suitability of the Information referred to herein (taking into account the specific investment objectives, financial situation and/or particular needs of each person in receipt of the Information) before making any investment and/or any purchase in reliance of the Information. Please refer to the actual research publications for important disclaimers and disclosures, where applicable.